Momenta Phama (MNTA) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. LITE
5. CL
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to Momenta Phama (MNTA) Misses Q4 EPS Views

Stifel Cuts PT on Momenta Pharma (MNTA) to $20; Glatopa Court Battle Becomes Increasingly Important

February 18, 2016 2:41 PM EST

Stifel trims its price target on Buy-rated Momenta Pharmaceuticals (Nasdaq: MNTA) from $29 to $20 following Q4 results reported earlier Thursday.

Analyst Thomas Shrader commented: Momenta reported 4Q15 GLATOPA revenues of $15.6 million, and $43.6 million for the year 2015, resulting in an EPS of $(0.43) for the... More